Skip to content
10-K

Annual Report

Processa Pharmaceuticals, Inc. PCSA

0001493152-26-011204

← back to feed
Filed
Mar 18, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 13, 2026 2.66M sh
Shares Diluted FY 2025 · Dec 31, 2025 1.31M sh
Shares Diluted restated FY 2025 · Dec 31, 2024 122.44K sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$11.39M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$11.25M
Cash And Equivalents FY 2025 · Dec 31, 2025 $5.54M
Cash And Equivalents FY 2025 · Dec 31, 2024 $1.19M
Stockholders Equity FY 2025 · Dec 31, 2025 $5.58M
Stockholders Equity FY 2025 · Dec 31, 2024 $1.7M
Stockholders Equity FY 2025 · Dec 31, 2023 $4.99M
Current Liabilities FY 2025 · Dec 31, 2025 $2.24M
Current Liabilities FY 2025 · Dec 31, 2024 $1.53M
Total Liabilities FY 2025 · Dec 31, 2025 $2.24M
Total Liabilities FY 2025 · Dec 31, 2024 $1.53M
Current Assets FY 2025 · Dec 31, 2025 $5.67M
Current Assets restated FY 2025 · Dec 31, 2024 $1.88M
Total Assets FY 2025 · Dec 31, 2025 $7.81M
Total Assets FY 2025 · Dec 31, 2024 $3.23M
Eps Diluted FY 2025 · Dec 31, 2025 −$10.36
Eps Diluted restated FY 2025 · Dec 31, 2024 −$96.78
Eps Basic FY 2025 · Dec 31, 2025 −$10.36
Eps Basic restated FY 2025 · Dec 31, 2024 −$96.78
Net Income FY 2025 · Dec 31, 2025 −$13.56M
Net Income FY 2025 · Dec 31, 2024 −$11.85M
Operating Income FY 2025 · Dec 31, 2025 −$13.99M
Operating Income FY 2025 · Dec 31, 2024 −$12.05M